Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPriority Health Medicare Formulary Coverage & PA |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentpriority healthPolicy N/A

    Priority Health Medicare Formulary (2026) - Drug List / Coverage Criteria

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the 2026 Priority Health Medicare formulary (drug list) describing covered drugs, restrictions (prior authorization, quantity limits, step therapy), member rights to exceptions, and how to use the formulary. It affects Priority Health Medicare members and their prescribers/pharmacies.

    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare Formulary (2026) - Drug List / Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material coverage changes
    Effective DateMay 1, 2026
    Last ReviewApr 21, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization from Priority Health Medicare before dispensing drugs marked 'PA' to ensure coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    May 1, 2026formulary effective/current as of
    4/21/2026document last updated
    30 daystransition supply
    72 hrsstandard decision timeframe
    24 hrsexpedited timeframe
    PA, QL, ST, HIutilization management types

    Formulary Coverage and Utilization Management

    General Coverage and Exception Process

    Covered when ALL of the following are met:

    Formulary Coverage Basics: Priority Health Medicare will generally cover drugs listed on the formulary when the drug is medically necessary, dispensed at a Priority Health Medicare network pharmacy, and all plan rules are followed.

    See Evidence of Coverage for benefit details.

    Utilization Management Requirements: Coverage is subject to any utilization management requirements noted for the product (e.g., Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST), Home Infusion (HI)).

    Providers must obtain PA or meet QL/ST/HI as specified for each drug.

    Exceptions and Timelines: Members or prescribers may request exceptions to cover non‑formulary drugs or to waive utilization controls; the plan generally decides within 72 hours or within 24 hours for expedited requests when clinically appropriate.
    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare Formulary (2026) - Drug List / Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material coverage changes
    Effective DateMay 1, 2026
    Last ReviewApr 21, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization from Priority Health Medicare before dispensing drugs marked 'PA' to ensure coverage.
    SourceLink
    On This Page
    Formulary Coverage and Utilization ManagementCodes, Abbreviations, and Quantity ExamplesPrescriber Responsibilities and Authorization RequirementsInitial Coverage ConstraintsStep Therapy Rules and InstancesSpecified Quantity Limits by ProductHome Infusion and Site-of-Care DesignationsBackground and ContextFormulary Abbreviations and Tier DefinitionsDocument Dates and Versioning
    72 hours (standard), 24 hours (expedited)

    Prescriber must provide a supporting medical statement when requesting an exception.

    Transition/Temporary Supply: When a drug is not on the formulary or has a restriction, Priority Health Medicare may provide a temporary transition or emergency supply (typically a 30‑day supply) while the member pursues an exception or alternative therapy.30 days

    Long‑term care residents may be eligible for a 31‑day emergency supply under specified conditions.

    Formulary coverage with utilization management

    Covered when the listed tier and any utilization management requirements are satisfied:

    Provider responsibility: Providers must submit documentation needed to support prior authorization requests or quantity overrides and must follow step‑therapy sequencing when indicated.

    See formulary guidance for acceptable documentation and timelines.

    Formulary coverage stance by tier and UM

    Coverage and utilization controls vary by tier:

    Tier definitions and controls: Formulary tiers (T1–T5) determine benefit placement; Tier 5 identifies specialty products which are limited to a 30‑day supply and commonly require prior authorization and quantity limits.

    Refer to the formulary legend for tier definitions and restrictions.

    Oncology agents

    Oncology oral antineoplastics and many specialty oncology agents are covered only when utilization controls are satisfied:

    Oncology PA and QL: Oral antineoplastics and targeted oncology agents require prior authorization and are subject to specified quantity limits (QL) as listed per agent (examples include lenalidomide, pomalidomide, LUMAKRAS, KISQALI, LYNPARZA).QL values as listed per agent (see formulary line items)

    Providers must submit a PA and include indication and requested quantity to obtain coverage.

    Therapy pack / pack‑specific limits: Some oncology agents use therapy packs or pack‑specific QLs; coverage follows the exact QL noted for that presentation.QL per pack as listed

    See individual drug entries for therapy pack QLs (e.g., XPOVIO, VITRAKVI, VENCLEXTA starting pack).

    Formulary coverage with utilization controls

    Most specialty products listed are covered only when prior authorization and any quantity limits are met:

    Specialty/formulary coverage rule: Drugs assigned to specialty tiers are covered subject to PA and QL as noted; many line items explicitly state 'Requirements/Limits = PA' and include QL expressed as EA or ML per time period.

    This section lists formulary placement and utilization controls rather than detailed clinical PA criteria.

    Formulary coverage mechanics (benefit-level)

    Benefit‑level mechanics that determine coverage placement and controls:

    Benefit determination: Coverage and member cost‑sharing are driven by tier placement (T1–T5); items marked PA require prior authorization and items with QL have defined quantity limits that must be observed.

    Tier 5 specialty drugs are noted as 30‑day supply only in the formulary legend.

    Formulary coverage and restrictions

    Coverage is provided according to tier when listed utilization restrictions are met:

    Formulary rule: Coverage and placement are determined by formulary tier; specific drugs carry utilization controls (PA, QL, ST, HI) which must be satisfied for reimbursement.

    Examples in the formulary show PA and QL applied to agents such as AUSTEDO, EVRYSDI, tetrabenazine and numerous CNS and specialty agents.

    Home infusion and site of care: Some IV or infusion products are flagged HI (Home Infusion) and may be covered under the medical benefit with specific site‑of‑care requirements; appropriate arrangements or PA may be required.

    See line items for HI designation and contact Customer Care for site‑of‑care instructions.

    Examples of coverage controls

    Examples illustrating how PA and QL are applied to specific products:

    tolvaptan (for hyponatremia) requires prior authorization and is limited to QL 120 EA per 30 days; therapy pack presentation has QL 56 EA per 28 days.QL 120 EA/30 days; therapy pack QL 56 EA/28 days

    PA and QL specified on formulary line items (chunk 201).

    FASENRA prefilled syringe 10 mg/0.5 mL requires prior authorization and has a quantity limit of 0.5 mL per 30 days.QL 0.5 mL/30 days

    See FASENRA line item for PA/QL details (chunk 203).

    Specialty drug coverage constraints

    Specialty injectables, biologics, and other high‑cost agents are covered only when PA/QL (and sometimes LA) rules are met:

    Specialty injectables and biologics: Numerous specialty injectables and biologic products require prior authorization and are subject to product‑specific quantity limits; some items also have Limited Availability (LA).QL varies by product (see line items)

    Examples include FASENRA (PA; QL), GATTEX (PA), and other rare‑disease or enzyme replacement therapies (chunks 203,206,208).

    Documentation requirement: Providers must submit supporting clinical documentation when requesting PA for specialty or limited‑availability products.

    Formulary and PA process references indicate required documentation and timelines.

    Covered with prior authorization and quantity limits

    Covered when tier placement and listed utilization requirements are fulfilled:

    Coverage condition: A drug will be covered according to its formulary tier only when any listed requirements (e.g., PA) are satisfied and the requested quantity does not exceed the listed QL.

    Line items include examples of PA and QL for hormonal agents and biologics (e.g., testosterone gels, LUPRON DEPOT, COSENTYX, DUPIXENT, ustekinumab).

    Quantity and PA enforcement: Requests exceeding QL or lacking PA may be denied unless an approved override or exception is granted.

    Providers should document intended dose, quantity and duration when requesting overrides.

    Product-level coverage with utilization controls

    Product‑level rules: each listed product is covered per its tier only when its utilization controls are met:

    Product entry rule: Each product listing includes tier assignment and, where indicated, utilization controls (PA, QL, ST, LA); coverage depends on meeting those controls.

    Examples: CYSTADROPS (PA; QL 20 mL/30 days), CYSTARAN (PA; QL 60 mL/28 days), OXERVATE (PA; QL 28 mL/30 days), RESTASIS (QL 60 EA/30 days).

    Ophthalmic specifics: Some ophthalmic agents have step therapy (ST) or QL requirements; when ST applies, prior trials of preferred agents must be documented.

    See ophthalmic section for travoprost (ST) and other ST examples.

    Specialty drug coverage criteria

    Specialty pulmonary and cystic fibrosis agents require PA and/or QL (and sometimes LA) to be covered:

    CF and pulmonary specialty agents: Cystic fibrosis and specialty pulmonary products (e.g., CAYSTON, KALYDECO, ORKAMBI, TRIKAFTA, OFEV, pirfenidone, ADEMPAS) require prior authorization and are subject to product‑specific quantity limits; some products may be Limited Availability (LA).

    Examples: TRIKAFTA therapy pack QL 84 EA per 28 days (or 56 EA per 28 days for certain packs); OFEV QL 60 EA per 30 days.

    Coverage prerequisite: Coverage requires fulfillment of PA and any QL/LA conditions for initial and ongoing therapy.

    Initial therapy constraints (e.g., tolvaptan) are handled by PA with specified QLs; see initial therapy criteria for examples.

    The formulary legend defines ED (Excluded Drug) as a prescription drug that is not normally covered by a Medicare Part D plan. Per the formulary, amounts paid by a member for an ED do not count toward the member’s total drug costs and therefore do not help the member qualify for catastrophic coverage. Coverage of ED-designated products may be limited to select Priority Medicare plan variants (for example, Priority Medicare Thrive and Thrive Plus) as noted in the legend.

    Notes in the formulary explain that an Excluded Drug (ED) is "not normally covered" under a Medicare Prescription Drug Plan and that the member’s payments for those drugs do not count toward catastrophic coverage. In practice, an ED entry signals the plan will not provide Part D coverage for that product except on specified plan variants.

    Some product entries in the drug listing are flagged NE (No Express Scripts) indicating the product is not available through Express Scripts home delivery; the clinical listing includes examples such as ENDOCET showing the NE flag for at least one strength.

    The document’s abbreviations and legend include ED as an exclusion marker, but the provided listing fragments do not contain a comprehensive line-by-line catalog of specific excluded drugs; ED appears as a legend term rather than as a full excluded-product list in the cited chunks.

    The formulary includes a clear Tier 5 (specialty) supply rule: products assigned to Tier 5 are limited to a 30-day supply only. This note appears in the legend and is reiterated alongside tier definitions.

    Across the cited sections there are no explicit line items listing clinically excluded drugs beyond the legend definition. The document references ED in the abbreviations, but specific excluded-drug entries are not present in these chunks.

    The provided segment does not list any Not Medically Necessary (NMN) determinations. In the chunks cited, there are no explicit NMN rules or product-level NMN statements.

    As noted in the formulary legend and repeated in tier definitions, Tier 5 (specialty) drugs are restricted to a 30-day supply. This supply limitation is a consistent rule for specialty-tier products in the document.

    The legend references the abbreviation ED — Excluded Drug, but within the provided chunks those exclusion markers are not mapped to particular product lines; ED is defined in the abbreviations without associated product-level entries in these excerpts.

    The document’s abbreviations list includes both ED (Excluded Drug) and NE (No Express Scripts), signaling that some products may be excluded from Part D coverage or unavailable via certain channels, even if specific affected products are not shown in the cited excerpts.

    Within this section the ED abbreviation appears in the legend, but the excerpt does not explicitly tie the exclusion code to individual products. In other words, the legend includes ED but the product lists in these chunks do not show specific excluded items.

    The sections reviewed do not contain specific Not Medically Necessary determinations for individual drugs. The formulary fragments provided include tiering and utilization controls but do not present NMN decision statements in these chunks.

    No explicit statements declaring particular drugs as not medically necessary are present in the cited passages. The document excerpts focus on tier placement and utilization requirements rather than NMN rulings.

    Codes, Abbreviations, and Quantity Examples

    Tetracyclines (selected)mixed
    doxycyclinehyclate, monohydrate, intravenous, oral capsule/tablet/suspension — various strengths listed (20 mg, 50 mg, 75 mg, 100 mg, 150 mg)
    minocyclineminocycline hcl oral capsule — listed (various strengths)
    tetracyclinetetracycline hcl oral capsule — listed
    Anticonvulsants (selected)mixed
    brivaracetam / BRIVIACToral solution and tablet — PA; QL (600 mL per 30 days solution; 60 EA per 30 days tablets)
    EPIDIOLEXPA; QL (500 mL per 30 days)
    FINTEPLAPA; QL (360 mL per 30 days)
    lamotrigineoral tablet/ER/chewable/dispersible — listed
    levetiracetamoral tablet/ER/oral solution/disintegrating tablets — some formulations PA; QL (60-90 EA per 30 days for disintegrating forms)
    perampanel / SUBVENITEoral suspension and tablets — PA; QL (680 mL per 28 days for suspension; 30 EA per 30 days for tablets)
    topiramateoral capsule sprinkle, solution, tablet — some formulations PA; QL (480 mL per 30 days for solution)
    valproic acidoral capsule and solution (250 mg/5 mL) — listed
    XCOPRI (cenobamate)various strengths and therapy packs — PA; QL (varies by strength: e.g., 56 EA per 28 days, 30–60 EA per 30 days depending on strength)
    clobazamoral suspension 2.5 mg/mL and tablets — PA; QL (480 mL per 30 days suspension; 60 EA per 30 days tablets)
    1–10 of 21
    1/3
    Formulary requirement codes / abbreviationsmixed
    PAPrior Authorization
    QLQuantity Limits (examples provided per product)
    STStep Therapy
    LALimited Availability
    NENo Express Scripts / Not applicable
    HIHome Infusion / Part B related
    Selected formulary anticonvulsant entries with limits/PAmixed
    BRIVIACT oral solution/tabletPA; QL (600 mL solution / 60 EA tablets per 30 days)
    EPIDIOLEXPA; QL (500 mL per 30 days)
    FINTEPLAPA; QL (360 mL per 30 days)
    XCOPRI (various strengths)PA; QL (examples: 56 EA per 28 days for certain daily-dose packs; 30–60 EA per 30 days for other strengths)
    clobazam suspension/tabletPA; QL (480 mL suspension per 30 days; 60 EA tablets per 30 days)
    VALTOCO (5/10/15/20 mg)PA; QL (10 EA per 30 days)
    VIGAFYDE / vigabatrinPA; QL (750 mL per 30 days)
    ZTALMYPA; QL (1100 mL per 30 days)
    Insulin supplies and pen needles (selected)mixed
    bd pen needlesmultiple bd pen needle types listed — Requirements/Limits = PA
    assure id insulin syringes / comfort assist syringeslisted — Requirements/Limits = PA
    embecta / autoshield deviceslisted — Requirements/Limits = PA
    Quantity limit examples (selected)mixed
    Fentanyl patch exampleQL example entries elsewhere in formulary (format shown above)
    Hydromorphone ER exampleQL example entries elsewhere in formulary
    Methadone solution exampleQL example: methadone HCl oral solution QL (600 mL per 30 days / 1200 mL per 30 days depending on strength)
    Formulary Tier Codesmixed
    T1Preferred generic
    T2Generic
    T3Preferred brand
    T4Non-preferred drug
    T5Specialty
    Requirement Abbreviations (legend)mixed
    EAEach
    MLMilliliters
    GMGrams
    HIHome Infusion
    LALimited Availability
    Formulary tier / requirement examples (selected)mixed
    Donepezil10 mg (T1) QL 60 EA per 30 days; 5 mg (T1) QL 30 EA per 30 days; 23 mg (T4) listed
    Galantaminehydrobromide ER (T4) and oral tablet (T2) listed
    Rivastigminelisted with QL (30 EA per 30 days or 60 EA per 30 days for tartrate)
    MemantineER (T4) QL 30 EA per 30 days; solution 2 mg/mL QL 300 mL per 30 days; tablets (T2) QL 60 EA per 30 days
    Antidepressants and SSRIs/SNRIs (selected)mixed
    AUVELITYT5; PA; QL (60 EA per 30 days); NE noted
    bupropionER/SR/XL and immediate-release forms listed (T2)
    mirtazapinevarious tablet strengths listed (T2/T3)
    EXXUA / EXXUA TITRATION PACKT5; PA; QL (30 EA per 30 days; titration pack 32 EA per 30 days)
    ZURZUVAET5; PA; QL (28 EA per 365 days for some strengths; 14 EA per 365 days for 30 mg)
    EMSAMT5; PA
    MARPLANT4; PA; QL (180 EA per 30 days)
    citalopramoral solution (T4) QL 600 mL per 30 days; tablets (T1) QL 45 EA per 30 days (10/20 mg) and 30 EA per 30 days (40 mg)
    desvenlafaxineER listed (T3) QL 30 EA per 30 days
    Examples of drugs with tier and requirement codesmixed
    DIFICIDOral suspension/tablet (T5) — ST; QL (136 mL per 10 days suspension; 20 EA per 10 days tablet)
    NAYZILAMT4 — PA; QL (10 EA per 30 days)
    SYMPAZANT5 — PA; QL (60 EA per 30 days)

    Prescriber Responsibilities and Authorization Requirements

    Prior Authorization

    Prior Authorization Required — prescribers must obtain PA for certain drugs

    Priority Health requires prior authorization (PA) for many medications — especially specialty, high-cost, oncology, certain GLP‑1 agents, insulin supplies, hormonal agents, and items flagged with HI (home infusion) or LA (limited availability). Prescribers must obtain approval before dispensing; drugs filled without an approved PA may be denied.

    • PA applies broadly to Tier 5 (Specialty) drugs — Tier 5 items are 30-day supply only.
    • Oncology agents frequently require both PA and Quantity Limits (QL); many oral and injectable oncology drugs in the formulary are labeled PA; QL (examples: lenalidomide, pomalidomide, VERZENIO, VITRAKVI, MEKINIST, NERLYNX).
    • Selected GLP‑1s and related glycemic agents require PA and have QLs (examples: MOUNJARO, OZEMPIC — see QL per 28/30‑day periods).
    • Insulin administration supplies and pen needles are flagged PA (examples: assured insulin syringes, pen needles such as embecta and bd pen needles).
    • Specialty hormonal agents require PA (examples: NORDITROPIN, OMNITROPE, certain leuprolide and depot products).
    • Home infusion (HI) and Limited Availability (LA) flags may trigger PA and special handling — drugs noted with HI often require coordination with infusion/home health services (examples: daptomycin, aztreonam, certain IV antibiotics).
    • Many specialty biologics and immunomodulators are PA; quantity limits are commonly applied (examples: adalimumab products, ustekinumab, XOLAIR — PA and QL shown).
    Documentation Required

    Exception request documentation and PA documentation expectations

    Provide supporting clinical documentation when requesting PA, exceptions, or step‑therapy overrides. For Part B vs Part D determinations, prescribers may need to submit physician statements describing the use and setting of the drug.

    • Exception requests: prescriber must explain medical rationale and submit supporting clinical statement; standard decisions are made within 72 hours of receiving the prescriber’s statement; expedited decisions within 24 hours when clinically warranted.
    • PA documentation should describe diagnosis, prior therapies tried (when applicable), dosing, intended duration, and location of administration (inpatient/infusion vs outpatient).
    • For formulary/tiering exceptions: include why alternatives are ineffective or cause adverse effects. Expect requests to reference the formulary page and last updated date.
    • Required documentation for topical anesthetics and lidocaine products: PA and QL units must be documented on the request (examples: lidocaine patch and LIDOCAN products flagged PA; QL = 90 EA per 30 days).
    Documentation Required

    Document QL values on requests; quantity‑limit documentation required

    When submitting PA or claims, include exact Quantity Limit (QL) units and clinical justification for any request exceeding QL. Failure to document QL units or to meet PA/ST/QL requirements can result in denial of coverage.

    • Document the requested QL (e.g., mL, EA, GM) on the PA form or claim to support benefit determination.
    • If requesting quantities above the listed QL, include clinical rationale explaining medical necessity and expected duration.
    • PA and QL frequently co-occur for injectable and specialty agents — omission of QL info or supporting clinical notes increases denial risk.
    • Examples of PA/QL pairs in the formulary: XIFAXAN (PA; QL 9 EA per 30 days for 200 mg; 60 EA per 30 days for 550 mg), many oncology agents (e.g., VERZENIO, VENCLEXTA — PA and specific QL), and biologics/immunomodulators (e.g., adalimumab products — PA; QL ml/28 days).
    • Enoxaparin and other parenteral anticoagulants have specific QLs that must be included on claims (examples: enoxaparin prefilled syringes QL per 30 days).
    Step Therapy

    Step Therapy Requirement — members may need to try alternatives first

    Step therapy (ST) is used for selected agents across classes; when ST is required, prescribers must show that required first‑line agents were tried and either failed or were not tolerated before PA for the subsequent agent will be approved.

    • ST is indicated in the formulary legend and applied to specific drugs (examples: DIFICID, FETZIMA, vilazodone, paliperidone ER products).
    • For ophthalmic agents, some products (difluprednate, loteprednol, travoprost bak‑free) are flagged ST — document prior therapy per ST requirements.
    • When ST applies, include dates and outcomes of prior therapies in the PA or exception request to expedite review.
    • The formulary includes an ST legend; specific step sequences are defined per drug entry (refer to formulary pages for details).
    Denial Risk

    Prior authorization triggers and denial risk

    Utilization management triggers that commonly lead to PA include specialty tiering, oncology agents, home infusion (HI) items, LA (limited availability), and listed high‑cost drugs. Expect denials if PA, QL, or ST requirements are not met.

    • PA/QL denials: many specialty and oncology drugs have both PA and QL — lack of approved PA or exceeding QL without justification may result in denial.
    • Home infusion trigger: drugs labeled HI require coordination with appropriate infusion services and may need additional documentation; claims without required arrangements risk denial.
    • Tier 5 specialty drugs are subject to PA and often limited to a 30‑day supply; ensure PA is obtained before dispensing.
    • Examples where PA/QL may trigger denial: tolvaptan (PA; QL), FASENRA (PA; QL), XIFAXAN (PA; QL), and many oncology products listed in the formulary.
    • Formulary abbreviations (B/D, PA, QL, ST, HI, LA, NE) are on the legend — follow them when preparing requests.

    Initial Coverage Constraints

    Initial therapy constraints (examples)

    Initial therapy constraints (examples):

    tolvaptan initial: tolvaptan requires prior authorization for initial therapy and is subject to quantity limits on initial and ongoing therapy as listed.QL 120 EA/30 days (therapy pack QL 56 EA/28 days)

    PA required for tolvaptan per formulary (chunk 201).

    Step Therapy Rules and Instances

    Policy ItemRequirement
    Step therapy (ST)
    Member must try specified preferred drugs before coverage of alternative agents is allowed (plan may require trial of Drug A prior to covering Drug B).
    AbbreviationNote
    ST
    Step Therapy abbreviation appears in the formulary legend; specific per‑drug step sequences are not detailed in the excerpt.
    DrugStep therapy requirement / Limits
    DIFICID (fidaxomicin) oral suspension/tablet
    Requirements/Limits = ST; QL (136 mL per 10 days for suspension; 20 EA per 10 days for tablets).
    Example branded agentStep therapy note
    FETZIMA
    Requirements/Limits = ST; QL (30 EA per 30 days) — step therapy applies for this branded agent as indicated.
    vilazodone
    Requirements/Limits = ST; QL (30 EA per 30 days) — step therapy required as listed.
    TRINTELLIX (vortioxetine)
    Listed among branded antidepressants where step therapy may apply (ST indicated for some agents).
    Legend entryImplication
    ST — Step Therapy (legend)
    ST appears in the abbreviations/legend but the provided document segments do not include detailed, per‑drug step sequences for many entries.
    ProductStep therapy / Other limits
    paliperidone ER (extended release) products
    Requirements/Limits = ST; QL (e.g., 30 EA per 30 days for some strengths; 60 EA per 30 days for others) — paliperidone ER products are noted with step therapy.
    ReferenceSummary
    Formulary abbreviations/legend
    Step therapy is referenced in the formulary legend (ST) but detailed step therapy rules are not included in this excerpt.
    ContextDetails
    ST listed as possible requirement
    Step therapy (ST) is listed among utilization management controls; specific sequences are not present in the provided segments.
    Legend itemNote
    ST included in abbreviation list
    The document includes ST (Step Therapy) in its abbreviations/legend; however, specific step therapy entries are not shown in these chunks.
    Topical productStep therapy indication
    calcitriol external (topical)
    Requirements/Limits = ST — calcitriol external is noted with step therapy as a requirement before coverage.
    Legend / AbbreviationObservation
    ST — Step Therapy
    Step therapy is referenced in the abbreviations/legend; the excerpt does not provide detailed per‑drug step sequences in this portion.
    AbbreviationSpecifics provided?
    ST (Step Therapy)
    Abbreviation appears in the document's abbreviations list, but no drug‑specific step therapy requirements are included in these chunks.
    Ophthalmic productStep therapy / Note
    travoprost (BAK‑free)
    Requirements/Limits = ST — travoprost (BAK‑free) is listed as subject to step therapy.
    Ophthalmic agentsStep therapy status
    difluprednate (ophthalmic)
    Requirements/Limits = ST — difluprednate is indicated as subject to step therapy for ophthalmic anti‑inflammatories.
    loteprednol (ophthalmic gel/suspension)
    Requirements/Limits = ST — loteprednol products are listed with ST where indicated.

    Specified Quantity Limits by Product

    XARELTO and related anticoagulant QL examples
    XARELTO oral tablet 10 mgQuantity limit: 30 EA per 30 days (example) — starter/pack distinctions provided separately
    XARELTO oral suspension (reconstituted)Quantity limit: 620 mL per 30 days
    Enoxaparin prefilled syringesQuantity limits vary by concentration (e.g., 60 mL per 30 days for 100 mg/mL)
    Unspecified quantity examples
    Common unspecified exampleExample quantity shown in document: 30 tablets (generic example for monthly supply)
    XARELTO 10 mgDocument cites 30 tablets per 30-day prescription as an example
    Topical NSAID QL example
    Diclofenac sodium external solution 1.5%Quantity limit: 750 mL per 30 days
    Diclofenac (other oral forms)Other diclofenac entries present but external solution has QL 750 mL/30 days
    Buprenorphine transdermal QL
    Buprenorphine transdermalQuantity limit: 4 EA per 28 days
    Buprenorphine formulationsDocument lists transdermal QL example as 4 EA; other formulations have separate entries
    Fentanyl patch QL
    Fentanyl transdermal patch (72 hour)Quantity limit: 10 EA per 30 days
    Fentanyl entries72-hour patch specifically listed with QL 10 EA/30 days
    Hydromorphone ER QL
    Hydromorphone ER oral tablet (extended release)Quantity limit: 60 EA per 30 days
    Hydromorphone other strengths/formsOther hydromorphone entries include varied QLs; ER tablet example is 60 EA/30 days
    Methadone solution QL
    Methadone HCl oral solution 10 mg/5 mLQuantity limit: 600 mL per 30 days
    Methadone other strengthsDocument also lists 1200 mL per 30 days for 5 mg/5 mL solution and tablet QLs (90–120 EA) depending on strength
    Morphine ER tablet QLs
    Morphine sulfate ER oral tabletsQuantity limits: 60–120 EA per 30 days depending on strength
    Morphine oral solutions/tabletsAdditional morphine formulations have ML or EA QLs (e.g., 900 mL for solutions; 180 EA for some tablets)
    ARIKAYCE QL
    ARIKAYCE (amikacin liposomal)Quantity limit: 235.2 mL per 28 days
    Inhaled/IV antibioticsDocument lists ARIKAYCE with specific mL-based QL (235.2 mL) among other HI-designated agents
    XIFAXAN QLs
    XIFAXAN oral tablet 200 mgQuantity limit: 9 EA per 30 days
    XIFAXAN oral tablet 550 mgQuantity limit: 60 EA per 30 days (separate entry)
    Assorted quantity-limit examples (document-wide)
    Multiple QL examplesDocument contains many specific QL entries (e.g., DIFICID 136 mL/10 days; BRIVIACT 600 mL/30 days or 60 EA/30 days; XCOPRI 56 EA/28 days; clobazam 480 mL/30 days or 60 EA/30 days)
    Reference guidanceSee per-drug lines in formulary for exact unit and period for each QL entry
    Memantine QL
    Memantine HCl (tablets)Quantity limit: 49 EA per 28 days
    Memantine other formsOral solution listed with QL 300 mL per 30 days for some formulations
    AUVELITY QL
    AUVELITYQuantity limit: 60 EA per 30 days
    AUVELITY requirementListed as Tier 5 with PA and QL where noted in formulary sections
    ZURZUVAE annual QL
    ZURZUVAE 30 mg oral capsuleQuantity limit: 14 EA per 365 days
    ZURZUVAE other strengthsOther ZURZUVAE strengths may have separate PA/QL entries in formulary
    Eletriptan QL
    Eletriptan (triptan)Quantity limit: 6 EA per 30 days
    Other triptansNaratriptan example listed with QL 12 EA per 30 days
    Posaconazole QL
    Posaconazole delayed-release tabletsQuantity limit: 93 EA per 30 days
    Other antifungal topical/systemic QLsDocument lists multiple GM/ML-based topical QLs (e.g., ciclopirox 180 GM/30 days)
    LUMAKRAS QL
    LUMAKRAS oral tablet 120 mgQuantity limit: 240 EA (per 30 days) as listed
    LUMAKRAS other strengthsOther strengths have separate QLs (e.g., 240 mg strength with lower QL) — see formulary line items
    XPOVIO therapy pack QLs
    XPOVIO therapy pack examplesQuantity limits vary by dosing pack (examples: 8 EA per 28 days for certain packs; other pack-specific QLs listed)
    XPOVIO dosing packsMultiple therapy-pack entries each specify PA and a pack-specific QL
    TAFINLAR QL
    TAFINLAR (soluble tablet)Quantity limit: 840 EA per 28 days
    TAFINLAR dosingDocument shows large EA QL for soluble/tablet formulations used in oncology
    VERZENIO and VITRAKVI examples
    VERZENIOQuantity limit: 60 EA per 30 days
    VITRAKVI oral solutionQuantity limit: 300 mL per 30 days (see separate entry)
    VITRAKVI and adalimumab QLs
    VITRAKVI oral solution (additional entry)Quantity limit listed: 300 (mL) per 30 days in formulary
    Adalimumab-adaz examplesMultiple presentation-based QLs provided (e.g., 2.4 mL per 28 days for 40 mg/0.4 mL auto-injector example)
    Abilify asimtufii IM QL
    Abilify asimtufii IM 720 mgQuantity limit: 2.4 (mL) per 56 days as listed
    Long-acting IM antipsychoticsFormulary shows ML-based QLs for several depot products (e.g., 0.75–5 mL per dosing period)
    LIVTENCITY QL
    LIVTENCITYQuantity limit: 336 EA per 28 days
    LIVTENCITY requirementListed with PA and large EA-based QL for supply period
    Antiretroviral QL patterns
    Common antiretrovirals (e.g., BIKTARVY, DOVATO, GENVOYA, STRIBILD)Typical quantity limit: 30 EA per 30 days (some products have 60 EA per 30 days)
    Select pack variantsCertain pack or starter-pack formulations have alternate QLs (see individual line entries)
    Assorted ML/GM QL examples
    VIREAD oral powder / SELZENTRY oral solutionExample QLs: 240 GM per 30 days (powder); 1800 mL per 30 days (SELZENTRY solution)
    GLP-1 and other ML/GM examplesMOUNJARO 2 mL per 28 days; OZEMPIC 3 mL per 28 days; other ML/GM-based limits provided per product
    ELIQUIS pack QL example
    ELIQUIS (standard packs) exampleQuantity limit: 74 EA per 30 days (pack-specific QLs also listed)
    ELIQUIS pack variantsOther pack-specific QLs shown (e.g., 222 EA, 592 EA for specialized packs)
    Enoxaparin QL by concentration
    Enoxaparin prefilled syringesQuantity limits vary by concentration (example: 60 mL per 30 days for 100 mg/mL)
    Enoxaparin other concentrationsDocument lists multiple concentration-specific QLs (24–60 mL per 30 days depending on presentation)
    XARELTO suspension and tablet QLs
    XARELTO oral suspension (reconstituted)Quantity limit: 620 mL per 30 days
    XARELTO tablet examplesTablets: 30 EA per 30 days (10 mg/20 mg) and 60 EA per 30 days (15 mg/2.5 mg) as listed
    VOYDEYA QL
    VOYDEYAQuantity limit: 180 EA per 30 days
    VOYDEYA requirementListed with PA; QL provided in formulary
    Amlodipine/benazepril combination QLs
    Amlodipine/benazepril combination productsQuantity limits by strength: 30 / 60 / 120 EA per 30 days depending on strength
    Combination product QL guidanceSee strength-specific line entries for exact QL per 30 days
    ENTRESTO sprinkle QL
    ENTRESTO oral capsule (sprinkle)Quantity limit: 240 EA per 30 days
    ENTRESTO other formsPack and strength-specific QLs may differ; refer to formulary line
    Various biologics and injectable QLs
    Selected biologics (examples)Quantity limits vary by product: e.g., COSENTYX 8 mL per 28 days; DUPIXENT 3.42 mL per 30 days; SELARSDI 0.5 mL per 28 days; SKYRIZI 1.2 mL per 56 days; ustekinumab-aekn 0.5–1 mL per 28 days; adalimumab-adaz 2.4 mL per 28 days
    Biologic QL unitsBiologic QLs expressed in mL per dosing period (28/30/56 days) or EA depending on presentation
    Dextroamphetamine QL
    Dextroamphetamine sulfate oral tablet 10 mgQuantity limit: 180 EA per 30 days
    Stimulant QLsOther stimulant strengths/forms have lower QLs (e.g., 60–120 EA per 30 days) depending on formulation
    Methylphenidate solution QL
    Methylphenidate HCl oral solution 10 mg/5 mLQuantity limit: 1500 mL per 30 days
    Methylphenidate other solution strengthsOther solution strengths listed with larger ML QLs (e.g., 3000 mL per 30 days for 5 mg/5 mL)
    AUSTEDO QL
    AUSTEDO oral tablet 12 mgQuantity limit: 120 EA per 30 days
    AUSTEDO other strengthsOther strengths listed with different QLs (e.g., 60 EA or 30 EA per 30 days)
    RADICAVA ORS QL
    RADICAVA ORSQuantity limit: 70 mL per 28 days
    RADICAVA starter kitStarter kit has same QL 70 mL per 28 days as listed
    AVONEX PEN QL
    AVONEX PEN intramuscular auto-injector kitQuantity limit: 4 EA per 28 days
    Multiple sclerosis injectablesSeveral MS injectables listed with PA and ML/EA QLs (e.g., Betaseron 15 EA/30 days)
    FASENRA QL
    FASENRA prefilled syringe 10 mg/0.5 mLQuantity limit: 0.5 mL per 30 days; prior authorization required
    FASENRA requirementListed as Tier 5 with PA and QL in formulary
    Tolvaptan QL
    Tolvaptan (hyponatremia)Quantity limit: 120 EA per 30 days (therapy pack QL 56 EA per 28 days); prior authorization required
    Tolvaptan therapy packTherapy pack QL specifically listed as 56 EA per 28 days
    LOKELMA QLs
    LOKELMA oral packet 10 gQuantity limit: 90 EA per 30 days
    LOKELMA oral packet 5 gQuantity limit: 30 EA per 30 days
    RELISTOR QL
    RELISTOR (oral)Quantity limit: 90 EA per 30 days
    RELISTOR and specialty GI agentsMultiple GI/rare-disease agents listed with PA and various QLs (see line items)
    Testosterone gel QLs
    Testosterone transdermal gels (strength examples)Quantity limits vary by strength: 150 GM/30 days; 300 GM/30 days; 37.5 GM/30 days; 75 GM/30 days
    Transdermal supply ruleMany testosterone formulations require PA and have strength-specific GM-per-30-days QLs
    Selected biologics QLs
    Selected biologics (COSENTYX, DUPIXENT, SELARSDI, SKYRIZI, ustekinumab-aekn, YESINTEK, adalimumab-adaz)Quantity limits vary by product (examples: 8 mL per 28 days; 3.42 mL per 30 days; 0.5 mL per 28 days; 1.2 mL per 56 days; 2.4 mL per 28 days)
    Biologic unit conventionsQLs expressed in mL/EA per specified period (28/30/56 days) depending on product presentation
    Ustekinumab-aekn QLs
    ustekinumab-aekn 45 mg/0.5 mLQuantity limit: 0.5 mL per 28 days
    ustekinumab-aekn 90 mg/mLQuantity limit: 1 mL per 28 days
    XELJANZ QLs
    XELJANZ oral solutionQuantity limit: 300 mL per 30 days
    XELJANZ oral tabletQuantity limit: 60 EA per 30 days; XR 11 mg: 30 EA per 30 days
    XELJANZ tablet/QXL examples
    XELJANZ oral tabletQuantity limit: 60 EA per 30 days
    XELJANZ XR 11 mgQuantity limit: 30 EA per 30 days
    Adalimumab-adaz QLs
    Adalimumab-adaz 40 mg/0.4 mL auto-injectorQuantity limit: 2.4 mL per 28 days (example listing)
    Adalimumab-adaz other presentationsOther presentations have proportional mL QLs (e.g., 0.2–3.2 mL per 28 days depending on strength)
    CYSTADROPS QL
    CYSTADROPS (ophthalmic)Quantity limit: 20 mL per 30 days
    Ophthalmic specialty QLsMultiple ophthalmic products listed with ML or GM QLs (e.g., RESTASIS 60 EA per 30 days; OXERVATE 28 mL per 30 days)
    CYSTARAN QL
    CYSTARAN (ophthalmic)Quantity limit: 60 mL per 28 days
    CYSTARAN noteListed with PA/QL as applicable in ophthalmic section
    RESTASIS QLs
    RESTASISQuantity limit: 60 EA per 30 days
    RESTASIS multidoseMultidose emulsion entry lists QL 5.5 mL per 30 days for multi-dose formulation
    TRIKAFTA therapy pack QLs
    TRIKAFTA therapy packQuantity limit: 84 EA per 28 days (therapy pack example)
    TRIKAFTA other therapy packAlternate therapy pack QL example listed as 56 EA per 28 days
    OFEV QL
    OFEV (nintedanib)Quantity limit: 60 EA per 30 days
    OFEV requirementListed as Tier 5 with PA/QL where noted
    Sodium oxybate QL
    Sodium oxybateQuantity limit: 540 mL per 30 days; prior authorization and limited availability noted
    Sodium oxybate programListed with PA and large ML-based QL reflecting controlled distribution

    Home Infusion and Site-of-Care Designations

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Background and Context

    Biological products are more complex than small-molecule drugs and often have biosimilar alternatives rather than traditional generics. The formulary explains that some biosimilars may be designated as interchangeable and substituted at the pharmacy consistent with state substitution laws, and it groups biologicals and other agents by therapeutic categories to support prescribers and pharmacists in locating coverage details.

    Formulary Abbreviations and Tier Definitions

    Biosimilar / Interchangeable biosimilar definition
    Biosimilar / Interchangeable biosimilarDefinition: Biosimilars are alternatives to original biological products; some are 'interchangeable' and may be substituted at the pharmacy without a new prescription depending on state law
    Substitution noteInterchangeable biosimilars may be substituted similarly to generics where state law permits
    Abbreviations — B/D and ED
    B/DPart B vs. Part D: indicates drugs that may be covered under Medicare Part B or Part D depending on use/setting; determination may require physician documentation
    EDExcluded Drug: not normally covered in a Medicare Prescription Drug Plan; costs do not count toward catastrophic coverage
    B/D definition — Part B vs Part D guidance
    B/D (coverage designation)Indicates Part B vs. Part D coverage; may require documentation about setting/use to determine benefit
    ED (Excluded Drug)Not normally covered by Part D; costs do not count toward catastrophic coverage; limited plan variants may cover EDs
    ED definition
    ED (Excluded Drug)Definition: Excluded Drug — not normally covered; payments do not count toward total drug costs and are not eligible for extra help under most plans
    Plan exceptionsPriority Medicare Thrive and Thrive Plus plans may offer coverage for some excluded drugs
    HI definition
    HI (Home Infusion)Definition: Home Infusion — drug may be covered under the medical benefit; contact Customer Care for specifics
    Contact infoCustomer Care phone provided for questions about HI coverage and arrangements
    PA definition
    PA (Prior Authorization)Definition: Prior Authorization — approval required from Priority Health Medicare before filling certain prescriptions; failure to obtain PA may result in noncoverage
    Provider actionPrescriber must request PA per plan procedures when PA is indicated on the formulary
    ST definition
    ST (Step Therapy)Definition: Step Therapy — requirement to try specified alternative drugs first before covering another drug for that condition
    Evidence requirementDocumentation of prior trial/failure may be required when ST is listed for a drug
    QL definition
    QL (Quantity Limit)Definition: Quantity Limit — Priority Health Medicare limits the amount of drug covered per specified time period (EA, ML, GM units)
    Unit typesCommon units used: EA (Each), ML (milliliters), GM (grams) — exact QL and period displayed per drug line
    Abbreviation legend — key items
    Abbreviation legend (short)T1–T5 indicate tiers (Preferred generic to Specialty); PA = Prior Authorization; QL = Quantity Limits; HI = Home Infusion; NE = No Express Scripts; ED = Excluded Drug
    Tier 5 supply ruleNote: Tier 5 drugs are 30-day supply only
    Tier definitions
    Tier definitions (T1–T5)T1 = Preferred generic; T2 = Generic; T3 = Preferred brand; T4 = Non-preferred drug; T5 = Specialty
    Tier 5 noteTier 5 drugs are limited to 30-day supply only (document note)
    PA / QL short labels and legend
    Short labels: PA / QLPA = Prior Authorization; QL = Quantity Limits — used on formulary entries to indicate required actions/limits
    Other abbreviationsST = Step Therapy; HI = Home Infusion; EA = Each; ML = Milliliters; GM = Grams; ED = Excluded Drug
    Tier 5 definition — 30-day supply rule
    Tier 5 supply rule (Tier 5 definition)Tier 5 specialty drugs are limited to a 30-day supply only as stated in the formulary note
    ImplicationPrescriptions for Tier 5 drugs beyond 30 days are not supported by the formulary supply rule unless specified elsewhere
    PA/QL abbreviation notes
    PA / QL abbreviation notesPA = Prior Authorization; QL = Quantity Limits; EA = Each; ML = Milliliters; GM = Grams — used to indicate utilization management on drug entries
    Provider considerationWhen QL or PA is listed, prescribers must document quantity, dose, and duration on requests/claims to support coverage
    Abbreviations list (summary)
    Abbreviations summaryCommon abbreviations used: PA, QL, HI, LA, ED, B/D, ST, EA, ML, GM
    Legend usageThese abbreviations appear next to each drug entry to indicate requirements or limitations that must be met for coverage
    Tiers and requirement short labels
    Tier short labels (T1–T5)T1–Preferred generic; T2–Generic; T3–Preferred brand; T4–Non-preferred; T5–Specialty
    Requirement short labelsPA = Prior Authorization; QL = Quantity Limits; ST = Step Therapy; HI = Home Infusion
    Abbreviation legend — utilization codes
    Utilization abbreviations (concise)PA (Prior Authorization); QL (Quantity Limits); ST (Step Therapy); LA (Limited Availability); B/D (Part B vs Part D); EA (Each)
    Usage guidanceAbbreviations indicate provider actions required or limits applied to each listed drug

    Document Dates and Versioning

    Formulary publication dates: this Drug List was stated as current as of May 1, 2026 and the document notes it was updated on 4/21/2026. Providers and pharmacies should confirm the most recent version with Priority Health Medicare Customer Care if needed.